Call for Innovative Therapeutic Approaches for Rare Diseases

Nikola Benin


The ERA-Net for Research Programmes on Rare Diseases (E-Rare) launches its 9th transnational call for funding multilateral research projects in the field “of Innovative Therapeutic Approaches for Rare Diseases”.

Please note that the Call text and Guidelines for applicants have been updated on the 02-01-17: rules for participation/eligibility in relation tothe Israel National Technological Innovation Authority

Please note the participation of a new funding agency: the Israel National Technological Innovation Authority (the “Innovation Authority)  (22-12-16)

Please note that the Call text has been updated on the 12-12-16: eligibility rules for Japan, link for the submission website.

Please note that the Guidelines for applicants has been updated on the 16-12-16: eligibility rules for Spain, Canada and Turkey.


Please note that the information provided on E-Rare website is not exhaustive. For all details of the call, eligibility criteria and sumbission rules please download and read documents provided in “Download documents” section.

The ERA-NET “E-Rare” for research programmes on rare diseases has been extended to a third phase “E-Rare-3” (2014-2019) to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of International Rare Disease Research Consortium (IRDiRC).

The following parties,

•    Austrian Science Fund (FWF), Austria
•    Research Foundation Flanders (FWO), Belgium, Flanders
•    Fund for Scientific Research – FNRS (F.R.S.-FNRS), Belgium, French-speaking community
•    Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
•    Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
•    Academy of Finland (AKA), Finland
•    French National Research Agency (ANR), France
•    Federal Ministry of Education and Research (BMBF), Germany
•    German Research Foundation (DFG), Germany
•    General Secretariat for Research and Technology (GSRT), Greece
•    National Research, Development and Innovation Office (NKFIH) of Hungary
•    Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
•    National Technological Innovation Authority (the “Innovation Authority), Israel
•    Italian Ministry of Health (MoH-IT), Italy
•    Foundation for Biomedical Research and Innovation, Japan
•    State Education Development Agency (VIAA), Latvia
•    National Centre for Research and Development (NCBR), Poland
•    Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
•    National Institute of Health Carlos III (ISCIII), Spain
•    Swiss National Science Foundation (SNSF), Switzerland
•    The Scientific and Technological Research Council of Turkey (TÜBITAK), Turkey

have decided to open the ninth E-Rare joint transnational call (JTC 2017) for funding multilateral research projects on rare diseases. The call is being opened simultaneously by the parties in their respective countries. In addition, Patient Organisations (PO) – represented in this call mostly by EURORDIS – may also co-fund selected projects based on their mandate and research topic interest.


The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach.

Topics: The research projects have to focus on the pre-clinical development of therapeutic approaches in suitable existing animal or cell models.
Therapeutic approaches can include:

a.    Cell-based therapy (e.g. somatic cell therapy, cell-based regenerative medicine, tissue engineering, therapies based on combination of cells with scaffolds or substrates, etc.)
b.    Gene therapy (e.g. transfer of nucleic acids for therapeutic purposes including DNA, RNA, oligonucleotides, etc.)
c.    Pharmacological therapy (e.g. use of chemicals or biopharmaceuticals including repurposing approaches, high throughput screening of molecules, etc.)

The following approaches and topics are excluded from the scope of the call:

a.    Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases
b.    Interventional clinical trials or any project enrolling patients
c.    Development of new cell or animal models. The relevant cell or animal model must be already established for the purpose of the project
d.    Surgery or radiation therapies

Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10.000 persons in the European Community, EC associated states and Canada.

For more information for partners and Fund subscribe to the Billetin PROJECT AND FUND

Price for 1 year € 120

6 months € 60


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s